Exercise:AntibodyStructurePrediction ans: Difference between revisions

From 22145
Jump to navigation Jump to search
(Created page with " __TOC__ = Antibody Structure Modelling — Teacher's Answers = '''Case study:''' SI135 antibody from chronic lymphocytic leukemia (CLL) '''LYRA prediction:''' [https://services.healthtech.dtu.dk/cgi-bin/webface2.cgi?jobid=6AD8166000282F67166ED625&wait=20 View the original modelling job] ''This page provides expected answers to Q1–Q11. Values marked [TO VERIFY] require inspection of the LYRA model, sequence alignment, or additional analyses.'' == Part 1 — Antibo...")
 
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
__TOC__
__TOC__


= Antibody Structure Modelling — Teacher's Answers =
= Antibody Structure Modelling — Answers =
 
'''Case study:''' SI135 antibody from chronic lymphocytic leukemia (CLL)


'''LYRA prediction:''' [https://services.healthtech.dtu.dk/cgi-bin/webface2.cgi?jobid=6AD8166000282F67166ED625&wait=20 View the original modelling job]
These answers refer to the SI135 antibody and the LYRA model generated from its heavy- and light-chain variable-region sequences. Residue numbering is identified as IMGT or PDB numbering where relevant.


''This page provides expected answers to Q1–Q11. Values marked [TO VERIFY] require inspection of the LYRA model, sequence alignment, or additional analyses.''
https://services.healthtech.dtu.dk/cgi-bin/webface2.cgi?jobid=6AD8166000282F67166ED625&wait=20


== Part 1 — Antibody modelling with LYRA ==
== Part 1 — Antibody modelling with LYRA ==


=== Q1. Framework template sequence similarity ===
=== Q1. Framework template similarity ===
 
'''Q1: what is the sequence similarity of the best H and L templates for the framework (FW)?'''


'''Answer:'''
LYRA selected the following templates for the antibody frameworks:


{| class="wikitable"
{| class="wikitable"
! Region
! Chain !! Selected template !! Sequence identity !! BLOSUM score
! Selected template
! Sequence identity
|-
|-
| Heavy-chain framework (VH)
| Heavy chain (VH) || '''3H42''' || '''80.5%''' || 514
| [TO VERIFY]
| [TO VERIFY]
|-
|-
| Light-chain framework (VL)
| Light chain (VL) || '''1W72''' || '''85.7%''' || 518
| [TO VERIFY]
| [TO VERIFY]
|}
|}


The framework templates are chosen according to their sequence compatibility with the target antibody, taking into account the CDR canonical structures.
The heavy-chain candidate 2UZI has a slightly higher sequence identity (81.7%), but a lower BLOSUM score (489) than 3H42. Thus, the template with the highest percentage of identical amino acids is not necessarily the one selected for modelling. Template selection also considers sequence similarity and the compatibility of the antibody's structural features.
 
The framework is relatively conserved among antibodies, and a high sequence identity usually facilitates reliable homology modelling.
 
LYRA reports both sequence identity and BLOSUM62 similarity scores. These should not be confused: sequence identity measures identical residues, whereas BLOSUM62 also accounts for conservative substitutions.


=== Q2. Light-chain type ===
=== Q2. Light-chain type ===


'''Q2: What is the light chain type? Is it the most common in humans?'''
SI135 has a '''lambda (λ) light chain'''. This is not the most common light-chain type in humans: approximately 60% of human antibodies have kappa (κ) light chains and 40% have lambda (λ) light chains, although the proportions vary.


'''Answer:'''
=== Q3. Differences between the target and template sequences ===


The SI135 antibody contains a '''lambda (λ) light chain'''.
The target and framework templates are relatively similar, but there are substitutions in both framework and CDR regions. Particularly informative differences in the selected loop-template alignments include:


The sequence is consistent with the IGLV3-21 light-chain family, which is associated with a well-characterized subset of CLL antibodies.
{| class="wikitable"
! Region !! Template → SI135 !! Possible consequence
|-
| H1 || S → T || Conservative change between polar residues
|-
| H2 || S → N || Changes side-chain size and hydrogen-bonding possibilities
|-
| H3 || R → N || Removes a positive charge
|-
| H3 || Q → T || Changes side-chain size and hydrogen-bonding properties
|-
| L2 || D → Y || Removes a negative charge and introduces a bulky aromatic group
|-
| L3 || L → S || Replaces a hydrophobic residue with a polar residue
|-
| L3 || S → D || Introduces a negatively charged residue
|-
| L3 || A → H || Introduces a larger side chain that may be protonated
|-
| L3 || D → P || Removes a negative charge and introduces a conformationally restricted residue
|}


Lambda is not the most common light-chain type in humans. Approximately 60% of human antibodies contain kappa (κ) light chains and 40% contain lambda (λ) light chains, although proportions vary between individuals and tissues.
The '''D → Y change in L2''' is particularly non-conservative (BLOSUM62 score −3). The '''D → P change in L3''' may also matter because proline strongly restricts backbone geometry. Changes at buried framework positions can influence stability, whereas changes in exposed CDR positions can influence the chemistry and shape of the binding site. The likely effect cannot be inferred from the substitution score alone.


=== Q3. Sequence differences between target and template ===
=== Q4. CDR lengths and modelling accuracy ===


'''Q3: where are the differences between target and template located? Which are the most drastic that could affect the modeling process (e.g. G->W)?'''
'''All six selected LYRA loop templates have the same loop-core length as their corresponding SI135 loops.'''


'''Answer:'''
{| class="wikitable"
! Loop !! PDB template !! Template sequence !! SI135 sequence !! Length
|-
| H1 || 3H42 || GFTFSSY || GFTFSTY || 7
|-
| H2 || 3H42 || SSSS || SSSN || 4
|-
| H3 || 2NR6 || VRQMD || VNTMD || 5
|-
| L1 || 2G75 || GNNIGSKS || GNNIGSKS || 8
|-
| L2 || 1W72 || DDS || YDN || 3
|-
| L3 || 3GHB || WDSGLSADW || WDSGSDHPW || 9
|}


The framework regions are generally more conserved than the CDRs, which are responsible for much of the sequence diversity in antibodies.
These are the '''loop-core sequences reported in the LYRA PDB annotations'''; broader CDR definitions include additional flanking residues.


The differences observed in the SI135 alignment should be classified according to their physicochemical properties.
Matching lengths make template-based modelling easier because insertions or deletions are not needed within the selected loop cores. However, matching length does not guarantee matching conformation. In particular, '''L1 has template canonical structure class 7 but predicted class 8''', even though its loop-core sequence is identical. This suggests that its modelled backbone should be interpreted cautiously.


Examples of substitutions with potentially important structural effects include:
=== Q5. Number of structural templates ===


* G → W: introduces a large aromatic side chain in place of a very small and flexible residue.
LYRA used '''five distinct PDB templates''':
* A → D: introduces a negatively charged side chain.
* D → K: reverses the formal side-chain charge.
* Substitutions involving proline: may restrict local backbone conformations.


Conservative substitutions, such as I → V or D → E, are generally less disruptive.
{| class="wikitable"
 
! PDB !! Region or regions modelled
However, the structural consequences depend on the position of the substitution. A change in the buried framework can be more important than a non-conservative substitution in an exposed loop.
|-
 
| '''3H42''' || Heavy-chain framework, H1, H2 and heavy/light-chain packing
'''SI135-specific substitutions:''' [TO VERIFY from the LYRA alignment]
|-
 
| '''2NR6''' || H3
=== Q4. CDR loop lengths ===
|-
 
| '''1W72''' || Light-chain framework and L2
'''Q4: Do the loops/CDR have the same length in target and template? What does it mean, in terms of expected accuracy?'''
|-
 
| '''2G75''' || L1
'''Answer:'''
|-
 
| '''3GHB''' || L3
The CDR loop lengths must be compared with those of the selected structural templates.
|}
 
The SI135 antibody contains the following CDR3 sequences:
 
<pre>
Heavy-chain CDR3:
ARDVNTMDV
Length: 9 amino acids
 
Light-chain CDR3:
QVWDSGSDHPWV
Length: 12 amino acids
</pre>
 
If the target and template loops have the same length and similar conformations, the model can generally be built more reliably.
 
Differences in loop length make modelling more difficult because insertions, deletions, or alternative loop conformations must be accommodated.
 
LYRA attempts to address this by selecting separate loop templates according to loop length and predicted canonical structure.
 
'''SI135 target/template length differences:''' [TO VERIFY]
 
=== Q5. Number and similarity of structural templates ===
 
'''Q5: How many templates were used? Which is the region for which the template is more dissimilar to the target sequence?'''
 
'''Answer:'''
 
LYRA uses structural templates for the heavy- and light-chain frameworks and can select additional templates for individual CDR loops.
 
There are eight modelled regions in total:
 
* Two framework regions (VH and VL).
* Three CDRs in the heavy chain.
* Three CDRs in the light chain.
 
However, the number of '''distinct PDB templates''' may be smaller than eight because several regions can be modelled using the same structure.
 
'''Number of distinct templates for SI135:''' [TO VERIFY]


'''Region with the least similar template:''' [TO VERIFY]
These structures fill nine framework, loop and packing assignments, but some PDB entries are reused.


CDR-H3 is frequently a challenging region to model because of its structural diversity, although the relatively long CDR-L3 of SI135 is also of particular interest.
The '''lowest percentage sequence identity''' among the selected loop cores occurs in '''L2''': only 1 of its 3 residues is identical to the template (33.3%). In contrast, '''L3 has the largest absolute number of substitutions''': 4 of its 9 residues differ from the selected template (55.6% identity). Both are comparatively uncertain regions, but for different reasons.


== Part 2 — Exploring the antibody structure ==
== Part 2 — Exploring the antibody structure in PyMOL ==


=== Q6. Shape of the antigen-binding site ===
=== Q6. Shape of the antigen-binding site ===


'''Q6: What is the general shape of the ABS: flat, a pocket, a mountain or a groove?'''
The predicted antigen-binding surface is best described as a '''shallow pocket or groove'''. The CDR loops form an uneven surface with a depression between protruding regions rather than a completely flat plane.
 
'''Answer:'''
 
The antigen-binding site is formed by the six CDR loops of the variable heavy and light chains.
 
Its surface can be classified qualitatively as flat, pocket-like, groove-like, or protruding (mountain-like).
 
'''SI135 classification:''' [TO VERIFY from the LYRA structure displayed as a surface]
 
The classification should be based on the overall geometry of the combined CDR surface rather than the shape of a single loop.
 
''Teaching point:'' The shape of the antigen-binding site can provide clues about molecular recognition, but it does not directly identify the antigen.
 
=== Q7. Longest and most protruding CDR loop ===
 
'''Q7: Which loop is the longest and protruding the most? Is this the most common case?'''
 
'''Answer:'''
 
SI135 has a relatively short heavy-chain CDR3 and a long light-chain CDR3.
 
<pre>
CDR-H3: ARDVNTMDV      (9 residues)
CDR-L3: QVWDSGSDHPWV  (12 residues)
</pre>


Using the short, structurally defined CDR boundaries, '''CDR-L3 is the longest CDR in this antibody'''.
The classification is qualitative: the appearance changes with the orientation of the model and how its molecular surface is displayed. The surface shape alone does not identify the antigen or establish binding specificity.


The loop that protrudes the most should be identified by inspecting the three-dimensional structure.
=== Q7. Longest and most protruding loop ===


'''Most protruding loop:''' [TO VERIFY in PyMOL]
'''CDR-L3 is the longest loop in the selected LYRA model''', with a 9-residue loop core (or 10 residues in the corresponding PDB loop selection including a flanking residue). CDR-L1 is the next longest in these definitions.


This is an unusual feature compared with the common situation in which CDR-H3 is the most variable and often the most prominent loop.
CDR-L3 is also a conspicuous protruding feature of the binding site. Depending on the viewing direction and whether backbone or surface protrusion is considered, '''H2 may appear to extend further than L3'''. Thus, the longest loop is not necessarily the one with the greatest height above the binding surface.


A long CDR does not necessarily protrude further than a short CDR, because its conformation can fold back towards the antibody framework.
This is not the usual pattern emphasized for human antibodies, where CDR-H3 is commonly the most variable and often a prominent part of the binding site. In SI135, CDR-H3 is relatively short.


== Part 3 — Somatic mutations ==
== Part 3 — Somatic mutations ==


=== Q8. Mutations potentially affecting antigen binding ===
=== Q8. Mutations within or near the CDRs ===


'''Q8: Which Mutations are located inside/near the CDRs? Which are the ones that are most likely to have an impact on the binding of the antibody?'''
The germline comparison identifies the following amino acid substitutions in the CDR regions ('''IMGT numbering'''; germline residue → SI135 residue):


'''Answer:'''
{| class="wikitable"
! Chain !! Region !! Mutation !! Interpretation
|-
| Heavy || CDR-H1 || S36T || Conservative polar substitution
|-
| Heavy || CDR-H2 || S63N || Changes side-chain geometry and hydrogen bonding
|-
| Heavy || CDR-H2 || '''Y64S''' || Removes a bulky aromatic side chain
|-
| Light || CDR-L2 || S65N || Changes side-chain geometry and hydrogen bonding
|-
| Light || CDR-L3 || S110G || Introduces glycine, which increases local backbone flexibility
|}


The somatic mutations must be identified by comparison with the closest germline V and J sequences, using IMGT/DomainGapAlign.
A further heavy-chain framework substitution, '''Y67C''', lies close to CDR-H2 and may influence the local structure. Other framework substitutions are present but are not necessarily directly involved in antigen contacts.


The SI135 sequences are consistent with IGHV3-21 and IGLV3-21 family usage, which is frequently associated with stereotyped B-cell receptors in CLL.
The strongest candidates for influencing antigen binding are '''Y64S in CDR-H2''' and potentially '''Y67C immediately outside this loop''', because they remove aromatic residues. The CDR substitutions S63N, S65N and S110G could also influence the local geometry or hydrogen-bonding interactions. In the BLOSUM62 matrix S → N has a positive score (+1), so it is not an especially drastic substitution by that measure alone.


'''Exact somatic mutations:''' [TO VERIFY using IMGT]
Whether any mutation actually changes antigen affinity depends on its position and interactions in the three-dimensional complex. '''Mutations relative to germline should not be confused with the differences between SI135 and the LYRA structural templates.'''


Mutations within the CDRs or in framework positions supporting the CDRs are particularly interesting.
== Part 4 — Electrostatic properties of the antigen-binding site ==


Mutations are more likely to affect binding when they:
=== Q9. Charged CDR residues ===


* Change the electrostatic properties of the binding site.
The important charged side chains are lysine (K) and arginine (R), which are usually positive, and aspartate (D) and glutamate (E), which are usually negative. Histidine (H) may carry a positive charge depending on its local environment and pH.
* Introduce or remove aromatic residues.
* Change hydrogen-bonding possibilities.
* Alter loop conformation or flexibility.
* Affect residues exposed towards the antigen.


Mutations affecting the charge or geometry of residues near the centre of the antigen-binding site are plausible candidates for having a functional effect.
The main contributors in the '''LYRA PDB loop selections''' are:


However, the impact of a mutation cannot be established confidently from the structure alone.
{| class="wikitable"
 
! Loop !! Charged residues !! LYRA PDB positions
''Teaching point:'' Mutations in the framework may indirectly alter binding by affecting the orientation or stability of the CDR loops.
|-
 
| H1 || No K, R, D or E || —
Differences introduced during V(D)J recombination, especially in CDR3, should not automatically be interpreted as somatic mutations.
|-
 
| H2 || No K, R, D or E || —
== Part 4 — Electrostatic properties ==
|-
 
| H3 || One D (negative) || H101
=== Q9. Charged residues in the CDRs ===
|-
| L1 || One K (positive) || L31
|-
| L2 || Two D residues (negative) || L51, L53
|-
| L3 || Two D residues (negative); one potentially protonated H || L92, L95A; H at L95B
|}


'''Q9: Identify the residues in the CDRs that mostly contribute to the charge distribution.'''
The short LYRA '''L2 loop-core sequence YDN''' contains one D; the corresponding PDB loop selection includes an additional flanking D at residue L53. This explains why either one or two aspartates may be counted depending on the CDR boundaries used.


'''Answer:'''
The negatively charged residues in L2 and L3 can contribute to a '''negative electrostatic patch''' around parts of the binding site. However, potential depends on solvent exposure, protonation and the three-dimensional arrangement of residues, not only on their number.


The most relevant charged amino acids are:
In a common electrostatic coloring convention, '''red indicates negative potential''' and '''blue indicates positive potential'''. The result from PyMOL's vacuum potential calculation is a qualitative representation.


* Positively charged: arginine (R), lysine (K).
=== Q10. Introducing a positive charge (optional) ===
* Negatively charged: aspartate (D), glutamate (E).


For SI135, the CDR3 sequences contain several charged residues.
Changing an exposed acidic residue near the centre of the antigen-binding site to lysine or arginine should make the local electrostatic potential more positive. For example, '''D → K''' replaces a negatively charged side chain with a positively charged one.


'''Heavy-chain CDR3:'''
After recalculating the surface potential, the region around the mutation would be expected to shift towards less red or more blue, depending on the color scale used. The effect can remain local and may be less obvious when other nearby charged residues dominate the surface potential.


<pre>
The reverse experiment also illustrates the same principle: replacing '''K31 in CDR-L1 with alanine''' removes a positive charge and can reduce a local positive electrostatic patch. A change in surface potential is not evidence by itself of improved or reduced antigen binding.
A R D V N T M D V
  + -        -
</pre>


This loop contains:
== Part 5 — Comparing antibody modelling approaches ==


* One arginine (R), positively charged.
=== Q11. LYRA versus ABodyBuilder2 ===
* Two aspartates (D), negatively charged.


'''Light-chain CDR3:'''
Both LYRA and ABodyBuilder2 predict a similar '''overall immunoglobulin fold''' for the heavy- and light-chain variable domains. The conserved framework beta-sheets are broadly consistent between the models.


<pre>
Differences are most likely to be visible in the '''CDR loops''', whose local backbone conformations may vary between a template-based and a deep-learning prediction. Comparisons of SI135 models show deviations in individual loops, particularly around '''CDR-H3 and CDR-L3'''; the local conformation of other loops, including L1, may also differ.
Q V W D S G S D H P W V
      -      -
</pre>
 
This loop contains:
 
* Two aspartates (D), negatively charged.
* One histidine (H), which may carry a positive charge depending on its environment and pH.
 
Both CDR3 loops therefore contain negatively charged residues.
 
Other charged residues in CDR1 and CDR2 also contribute to the overall charge distribution.
 
The surface distribution must be inspected in PyMOL because residues that are close in sequence are not necessarily close in three-dimensional space.
 
A local concentration of aspartate residues could produce a negatively charged region at the antigen-binding surface.
 
''Teaching point:'' Electrostatic potential reflects the spatial distribution of charges, not simply the total number of charged amino acids.
 
=== Q10. Effect of introducing a positive charge (optional) ===
 
'''Q10: (optional) Mutate some residues in order to have a positive charge in the middle of the antigen binding site, then recalculate the electrostatic potentials. Can you see the changes?'''
 
'''Answer:'''
 
Introducing a positively charged residue, such as lysine (K) or arginine (R), should increase the local positive electrostatic potential.
 
For example, replacing an exposed aspartate (D) with lysine (K) in a CDR could reverse the local charge.
 
After recalculating the electrostatic potential, a change in surface coloring should become visible near the mutated residue.
 
The extent of the change depends on the location and conformation of the new side chain.
 
A more positive surface does not necessarily imply stronger antigen binding, because the properties of the antigen must also be considered.
 
== Part 5 — Comparison of modelling approaches ==
 
=== Q11. Comparison between LYRA and ABodyBuilder2 ===
 
'''Q11: Go to the AbodyBuilder 2 site and make a new structure prediction. Download the PDB file and compare with the model generated by LYRA. Can you see some differences?'''
 
'''Answer:'''
 
LYRA and ABodyBuilder2 use different approaches to antibody structure prediction.


{| class="wikitable"
{| class="wikitable"
! LYRA
! LYRA !! ABodyBuilder2
! ABodyBuilder2
|-
| Traditional template-based homology modelling
| Deep-learning-based structure prediction
|-
|-
| Selects framework and CDR templates from known experimental structures
| Template-based homology modelling || Deep-learning-based structure prediction
| Uses a neural network trained on antibody structures
|-
|-
| Uses canonical loop structures and loop grafting
| Uses selected framework and CDR structural templates || Predicts antibody structure from the amino acid sequences
| Learns structural patterns from training data
|-
|-
| Quality depends strongly on suitable templates
| Accuracy depends in part on template suitability || Reports prediction-error estimates for different structural regions
| Provides prediction-error estimates for different antibody regions
|}
|}


The overall immunoglobulin fold is expected to be similar in both models.
When the structures are superimposed, the frameworks are expected to agree more closely than the variable loops. Any differences should be interpreted as '''model uncertainty''', not as proof that one model is correct. Neither prediction alone establishes the experimentally observed antibody conformation or its antigen specificity.
 
Differences may occur in:
 
* CDR loop conformations, particularly CDR-H3 or unusual loops.
* Relative orientations of the heavy and light chains.
* Side-chain conformations.
 
'''Specific differences between the SI135 models:''' [TO VERIFY after structural superposition]
 
The models can be compared in PyMOL using:
 
<pre>
align ABodyBuilder2, LYRA
</pre>
 
Replace the object names with those used in the PyMOL session.
 
The RMSD obtained after structural alignment provides a quantitative measure of structural differences.
 
''Teaching point:'' Agreement between two predictions can increase confidence in a structural hypothesis, but does not establish experimental accuracy.


== Summary ==
== Summary ==


This exercise illustrates several important principles:
* The SI135 antibody contains a lambda light chain.
 
* LYRA selected frameworks 3H42 (80.5% identity) and 1W72 (85.7% identity).
* Antibody frameworks are relatively conserved, whereas CDR loops provide sequence and structural diversity.
* Five distinct structural templates were used for framework, loop and packing modelling.
* Template-based modelling is influenced by sequence similarity, loop length, and canonical structure.
* All selected loop cores have matching target/template lengths, but CDR-L1 differs in its canonical structure classification.
* CDR-H3 is often particularly variable, but other CDRs may also present modelling challenges.
* CDR-L2 has the lowest loop-core sequence identity, while CDR-L3 has the greatest number of residue substitutions.
* Somatic mutations may affect antigen recognition by changing the structural or chemical properties of the binding surface.
* CDR-L3 is the longest loop; the apparent extent of protrusion depends on the representation and viewing direction.
* Electrostatic properties depend on the three-dimensional arrangement of charged residues.
* CDR mutations can influence binding by changing side-chain chemistry or loop conformation, but effects on affinity require experimental validation.
* Deep-learning tools provide an alternative to traditional homology modelling, but predicted structures must still be evaluated critically.
* The electrostatic properties of the binding site reflect the positions of charged residues, especially aspartates in the light-chain CDRs.
 
* Template-based and deep-learning predictions generally agree on the immunoglobulin framework but may differ in CDR conformations.
== References ==
 
* [https://services.healthtech.dtu.dk/cgi-bin/webface2.cgi?jobid=6AD8166000282F67166ED625&wait=20 SI135 LYRA modelling results]
* [https://services.healthtech.dtu.dk/services/LYRA-1.0/ LYRA — DTU Health Tech]
* [https://www.imgt.org/ IMGT immunogenetics]
* [https://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/sabpred/abodybuilder2/ ABodyBuilder2]
* [https://pmc.ncbi.nlm.nih.gov/articles/PMC7015129/ Antibody sequences and antigen recognition in CLL]

Latest revision as of 04:00, 21 October 2026

Antibody Structure Modelling — Answers

These answers refer to the SI135 antibody and the LYRA model generated from its heavy- and light-chain variable-region sequences. Residue numbering is identified as IMGT or PDB numbering where relevant.

https://services.healthtech.dtu.dk/cgi-bin/webface2.cgi?jobid=6AD8166000282F67166ED625&wait=20

Part 1 — Antibody modelling with LYRA

Q1. Framework template similarity

LYRA selected the following templates for the antibody frameworks:

Chain Selected template Sequence identity BLOSUM score
Heavy chain (VH) 3H42 80.5% 514
Light chain (VL) 1W72 85.7% 518

The heavy-chain candidate 2UZI has a slightly higher sequence identity (81.7%), but a lower BLOSUM score (489) than 3H42. Thus, the template with the highest percentage of identical amino acids is not necessarily the one selected for modelling. Template selection also considers sequence similarity and the compatibility of the antibody's structural features.

Q2. Light-chain type

SI135 has a lambda (λ) light chain. This is not the most common light-chain type in humans: approximately 60% of human antibodies have kappa (κ) light chains and 40% have lambda (λ) light chains, although the proportions vary.

Q3. Differences between the target and template sequences

The target and framework templates are relatively similar, but there are substitutions in both framework and CDR regions. Particularly informative differences in the selected loop-template alignments include:

Region Template → SI135 Possible consequence
H1 S → T Conservative change between polar residues
H2 S → N Changes side-chain size and hydrogen-bonding possibilities
H3 R → N Removes a positive charge
H3 Q → T Changes side-chain size and hydrogen-bonding properties
L2 D → Y Removes a negative charge and introduces a bulky aromatic group
L3 L → S Replaces a hydrophobic residue with a polar residue
L3 S → D Introduces a negatively charged residue
L3 A → H Introduces a larger side chain that may be protonated
L3 D → P Removes a negative charge and introduces a conformationally restricted residue

The D → Y change in L2 is particularly non-conservative (BLOSUM62 score −3). The D → P change in L3 may also matter because proline strongly restricts backbone geometry. Changes at buried framework positions can influence stability, whereas changes in exposed CDR positions can influence the chemistry and shape of the binding site. The likely effect cannot be inferred from the substitution score alone.

Q4. CDR lengths and modelling accuracy

All six selected LYRA loop templates have the same loop-core length as their corresponding SI135 loops.

Loop PDB template Template sequence SI135 sequence Length
H1 3H42 GFTFSSY GFTFSTY 7
H2 3H42 SSSS SSSN 4
H3 2NR6 VRQMD VNTMD 5
L1 2G75 GNNIGSKS GNNIGSKS 8
L2 1W72 DDS YDN 3
L3 3GHB WDSGLSADW WDSGSDHPW 9

These are the loop-core sequences reported in the LYRA PDB annotations; broader CDR definitions include additional flanking residues.

Matching lengths make template-based modelling easier because insertions or deletions are not needed within the selected loop cores. However, matching length does not guarantee matching conformation. In particular, L1 has template canonical structure class 7 but predicted class 8, even though its loop-core sequence is identical. This suggests that its modelled backbone should be interpreted cautiously.

Q5. Number of structural templates

LYRA used five distinct PDB templates:

PDB Region or regions modelled
3H42 Heavy-chain framework, H1, H2 and heavy/light-chain packing
2NR6 H3
1W72 Light-chain framework and L2
2G75 L1
3GHB L3

These structures fill nine framework, loop and packing assignments, but some PDB entries are reused.

The lowest percentage sequence identity among the selected loop cores occurs in L2: only 1 of its 3 residues is identical to the template (33.3%). In contrast, L3 has the largest absolute number of substitutions: 4 of its 9 residues differ from the selected template (55.6% identity). Both are comparatively uncertain regions, but for different reasons.

Part 2 — Exploring the antibody structure in PyMOL

Q6. Shape of the antigen-binding site

The predicted antigen-binding surface is best described as a shallow pocket or groove. The CDR loops form an uneven surface with a depression between protruding regions rather than a completely flat plane.

The classification is qualitative: the appearance changes with the orientation of the model and how its molecular surface is displayed. The surface shape alone does not identify the antigen or establish binding specificity.

Q7. Longest and most protruding loop

CDR-L3 is the longest loop in the selected LYRA model, with a 9-residue loop core (or 10 residues in the corresponding PDB loop selection including a flanking residue). CDR-L1 is the next longest in these definitions.

CDR-L3 is also a conspicuous protruding feature of the binding site. Depending on the viewing direction and whether backbone or surface protrusion is considered, H2 may appear to extend further than L3. Thus, the longest loop is not necessarily the one with the greatest height above the binding surface.

This is not the usual pattern emphasized for human antibodies, where CDR-H3 is commonly the most variable and often a prominent part of the binding site. In SI135, CDR-H3 is relatively short.

Part 3 — Somatic mutations

Q8. Mutations within or near the CDRs

The germline comparison identifies the following amino acid substitutions in the CDR regions (IMGT numbering; germline residue → SI135 residue):

Chain Region Mutation Interpretation
Heavy CDR-H1 S36T Conservative polar substitution
Heavy CDR-H2 S63N Changes side-chain geometry and hydrogen bonding
Heavy CDR-H2 Y64S Removes a bulky aromatic side chain
Light CDR-L2 S65N Changes side-chain geometry and hydrogen bonding
Light CDR-L3 S110G Introduces glycine, which increases local backbone flexibility

A further heavy-chain framework substitution, Y67C, lies close to CDR-H2 and may influence the local structure. Other framework substitutions are present but are not necessarily directly involved in antigen contacts.

The strongest candidates for influencing antigen binding are Y64S in CDR-H2 and potentially Y67C immediately outside this loop, because they remove aromatic residues. The CDR substitutions S63N, S65N and S110G could also influence the local geometry or hydrogen-bonding interactions. In the BLOSUM62 matrix S → N has a positive score (+1), so it is not an especially drastic substitution by that measure alone.

Whether any mutation actually changes antigen affinity depends on its position and interactions in the three-dimensional complex. Mutations relative to germline should not be confused with the differences between SI135 and the LYRA structural templates.

Part 4 — Electrostatic properties of the antigen-binding site

Q9. Charged CDR residues

The important charged side chains are lysine (K) and arginine (R), which are usually positive, and aspartate (D) and glutamate (E), which are usually negative. Histidine (H) may carry a positive charge depending on its local environment and pH.

The main contributors in the LYRA PDB loop selections are:

Loop Charged residues LYRA PDB positions
H1 No K, R, D or E —
H2 No K, R, D or E —
H3 One D (negative) H101
L1 One K (positive) L31
L2 Two D residues (negative) L51, L53
L3 Two D residues (negative); one potentially protonated H L92, L95A; H at L95B

The short LYRA L2 loop-core sequence YDN contains one D; the corresponding PDB loop selection includes an additional flanking D at residue L53. This explains why either one or two aspartates may be counted depending on the CDR boundaries used.

The negatively charged residues in L2 and L3 can contribute to a negative electrostatic patch around parts of the binding site. However, potential depends on solvent exposure, protonation and the three-dimensional arrangement of residues, not only on their number.

In a common electrostatic coloring convention, red indicates negative potential and blue indicates positive potential. The result from PyMOL's vacuum potential calculation is a qualitative representation.

Q10. Introducing a positive charge (optional)

Changing an exposed acidic residue near the centre of the antigen-binding site to lysine or arginine should make the local electrostatic potential more positive. For example, D → K replaces a negatively charged side chain with a positively charged one.

After recalculating the surface potential, the region around the mutation would be expected to shift towards less red or more blue, depending on the color scale used. The effect can remain local and may be less obvious when other nearby charged residues dominate the surface potential.

The reverse experiment also illustrates the same principle: replacing K31 in CDR-L1 with alanine removes a positive charge and can reduce a local positive electrostatic patch. A change in surface potential is not evidence by itself of improved or reduced antigen binding.

Part 5 — Comparing antibody modelling approaches

Q11. LYRA versus ABodyBuilder2

Both LYRA and ABodyBuilder2 predict a similar overall immunoglobulin fold for the heavy- and light-chain variable domains. The conserved framework beta-sheets are broadly consistent between the models.

Differences are most likely to be visible in the CDR loops, whose local backbone conformations may vary between a template-based and a deep-learning prediction. Comparisons of SI135 models show deviations in individual loops, particularly around CDR-H3 and CDR-L3; the local conformation of other loops, including L1, may also differ.

LYRA ABodyBuilder2
Template-based homology modelling Deep-learning-based structure prediction
Uses selected framework and CDR structural templates Predicts antibody structure from the amino acid sequences
Accuracy depends in part on template suitability Reports prediction-error estimates for different structural regions

When the structures are superimposed, the frameworks are expected to agree more closely than the variable loops. Any differences should be interpreted as model uncertainty, not as proof that one model is correct. Neither prediction alone establishes the experimentally observed antibody conformation or its antigen specificity.

Summary

  • The SI135 antibody contains a lambda light chain.
  • LYRA selected frameworks 3H42 (80.5% identity) and 1W72 (85.7% identity).
  • Five distinct structural templates were used for framework, loop and packing modelling.
  • All selected loop cores have matching target/template lengths, but CDR-L1 differs in its canonical structure classification.
  • CDR-L2 has the lowest loop-core sequence identity, while CDR-L3 has the greatest number of residue substitutions.
  • CDR-L3 is the longest loop; the apparent extent of protrusion depends on the representation and viewing direction.
  • CDR mutations can influence binding by changing side-chain chemistry or loop conformation, but effects on affinity require experimental validation.
  • The electrostatic properties of the binding site reflect the positions of charged residues, especially aspartates in the light-chain CDRs.
  • Template-based and deep-learning predictions generally agree on the immunoglobulin framework but may differ in CDR conformations.